SARS-CoV-2辅助蛋白ORF8的功能及研究进展

doi:10.11958/20220531

天津医药 ›› 2022, Vol. 50 ›› Issue (10): 1110-1114.doi: 10.11958/20220531

SARS-CoV-2辅助蛋白ORF8的功能及研究进展

付亚男(), 曾凤, 饶晶晶, 黄艳萍, 刘志新, 刘龙()

湖北医药学院基础医学院（邮编442000）

收稿日期:2022-04-12 修回日期:2022-05-27 出版日期:2022-10-15 发布日期:2022-10-20
通讯作者: 刘龙 E-mail:3064909472@qq.com;liulong2015@outlook.com
作者简介:付亚男（1999）,女,硕士在读,主要从事病毒感染与免疫方面研究。E-mail： 3064909472@qq.com
基金资助:
国家自然科学基金资助项目(82002149);,湖北省卫生健康委员会项目(WJ2021M059)

The research progress and function of SARS-CoV-2 accessory protein ORF8

FU Ya'nan(), ZENG Feng, RAO Jingjing, HUANG Yanping, LIU Zhixin, LIU Long()

School of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China

Received:2022-04-12 Revised:2022-05-27 Published:2022-10-15 Online:2022-10-20
Contact: LIU Long E-mail:3064909472@qq.com;liulong2015@outlook.com

付亚男, 曾凤, 饶晶晶, 黄艳萍, 刘志新, 刘龙. SARS-CoV-2辅助蛋白ORF8的功能及研究进展[J]. 天津医药, 2022, 50(10): 1110-1114.

FU Ya'nan, ZENG Feng, RAO Jingjing, HUANG Yanping, LIU Zhixin, LIU Long. The research progress and function of SARS-CoV-2 accessory protein ORF8[J]. Tianjin Medical Journal, 2022, 50(10): 1110-1114.

摘要/Abstract

摘要：

新型冠状病毒（SARS-CoV-2）与2002年开始流行的冠状病毒（SARS-CoV）基因组相似,编码多种病毒蛋白。其中辅助蛋白ORF8与SARS-CoV ORF8有较低的序列同源性,且有快速进化和突变的特征,具有抑制Ⅰ型干扰素、下调主要组织相容性复合体Ⅰ（MHCⅠ）表达等功能。该文就SARS-CoV-2辅助蛋白ORF8的结构、功能及对COVID-19的诊断治疗前景进行综述。

关键词: SARS病毒, 免疫逃避, 突变, 进化,分子, 新型冠状病毒, ORF8

Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a genome similar to that of the SARS-CoV, which has been circulating since 2002 and encodes multiple viral proteins. The accessory protein ORF8 has low sequence homology with SARS-CoV ORF8, and has characteristics of rapid evolution and mutation. It has functions of inhibiting type I interferon and down-regulating the expression of major histocompatibility complex I (MHC I). This paper reviews the structure and function of accessory protein ORF8 and the diagnostic and therapeutic prospects for COVID-19.

Key words: SARS virus, immune escape, mutation, evolution, molecular, SARS-CoV-2, ORF8

中图分类号:

R373.1

图/表 1

参考文献 33

[1]	World Health Organization. WHO Coronavirus(COVID-19)Dashboard[EB/OL]. (2022-05-25)[2022-05-25]. https://covid19.who.int.
[2]	GORDON D E, HIATT J, BOUHADDOU M, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms[J]. Science, 2020, 370(6521):eabe9403. doi: 10.1126/science.abe9403.
[3]	VALCARCEL A, BENSUSSEN A, ALVAREZ-BUYLLA E R, et al. Structural analysis of SARS-CoV-2 ORF8 protein:pathogenic and therapeutic implications[J]. Front Genet, 2021, 12:693227. doi: 10.3389/fgene.2021.693227.
[4]	FLOWER T G, BUFFALO C Z, HOOY R M, et al. Structure of SARS-CoV-2 ORF8,a rapidly evolving immune evasion protein[J]. Proc Natl Acad Sci U S A, 2021, 118(2):e2021785118. doi: 10.1073/pnas.2021785118.
[5]	TAN Y, SCHNEIDER T, LEONG M, et al. Novel immunoglobulin domain proteins provide insights into evolution and pathogenesis of SARS-CoV-2-related viruses[J]. mBio, 2020, 11(3):e00760-20. doi: 10.1128/mBio.00760-20.
[6]	WANG X, LAM J Y, WONG W M, et al. Accurate diagnosis of COVID-19 by a novel immunogenic secreted SARS-CoV-2 ORF8 protein[J]. mBio, 2020, 11(5):e02431-20. doi: 10.1128/mBio.02431-20.
[7]	ZINZULA L. Lost in deletion:The enigmatic ORF8 protein of SARS-CoV-2[J]. Biochem Biophys Res Commun, 2021, 538:116-124. doi: 10.1016/j.bbrc.2020.10.045.
[8]	LI J Y, LIAO C H, WANG Q, et al. The ORF6,ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway[J]. Virus Res, 2020, 286:198074. doi: 10.1016/j.virusres.2020.198074.
[9]	RASHID F, SULEMAN M, SHAH A, et al. Mutations in SARS-CoV-2 ORF8 altered the bonding network with interferon regulatory factor 3 to evade host immune system[J]. Front Microbiol, 2021, 12:703145. doi: 10.3389/fmicb.2021.703145.
[10]	RASHID F, DZAKAH E E, WANG H, et al. The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta[J]. Virus Res, 2021, 296:198350. doi: 10.1016/j.virusres.2021.198350.
[11]	ZHANG Y, CHEN Y, LI Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Iota[J]. Proc Natl Acad Sci U S A, 2021, 118(23):e2024202118. doi: 10.1073/pnas.2024202118.
[12]	MCGEACHY M J, CUA D J, GAFFEN S L. The IL-17 family of cytokines in health and disease[J]. Immunity, 2019, 50(4):892-906. doi: 10.1016/j.immuni.2019.03.021.
[13]	LIN X, FU B, YIN S, et al. ORF8 contributes to cytokine storm during SARS-CoV-2 infection by activating IL-17 pathway[J]. iScience, 2021, 24(4):102293. doi: 10.1016/j.isci.2021.102293.
[14]	SUNG S C, CHAO C Y, JENG K S, et al. The 8ab protein of SARS-CoV is a luminal ER membrane-associated protein and induces the activation of ATF6[J]. Virology, 2009, 387(2):402-413. doi: 10.1016/j.virol.2009.02.021.
[15]	MUTH D, CORMAN V M, ROTH H, et al. Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission[J]. Sci Rep, 2018, 8(1):15177. doi: 10.1038/s41598-018-33487-8.
[16]	OOSTRA M, DE HAAN C A, ROTTIER P J. The 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8[J]. J Virol, 2007, 81(24):13876-13888. doi: 10.1128/JVI.01631-07.
[17]	HELENIUS A, AEBI M. Intracellular functions of N-linked glycans[J]. Science, 2001, 291(5512):2364-2369. doi: 10.1126/science.291.5512.2364.
[18]	LE T M, WONG H H, TAY F P, et al. Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus[J]. FEBS J, 2007, 274(16):4211-4222. doi: 10.1111/j.1742-4658.2007.05947.x.
[19]	WONG H H, FUNG T S, FANG S, et al. Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3[J]. Virology, 2018, 515:165-175. doi: 10.1016/j.virol.2017.12.028.
[20]	CHEN C Y, PING Y H, LEE H C, et al. Open reading frame 8a of the human severe acute respiratory syndrome coronavirus not only promotes viral replication but also induces apoptosis[J]. J Infect Dis, 2007, 196(3):405-415. doi: 10.1086/519166.
[21]	PAL A, DOBHAL S, DEY K K, et al. Polymorphic landscape of SARS-CoV-2 genomes isolated from Indian population in 2020 demonstrates rapid evolution in ORF3a, ORF8, nucleocapsid phosphoprotein and spike glycoprotein[J]. Comput Biol Chem, 2021, 95:107594. doi: 10.1016/j.compbiolchem.2021.107594.
[22]	GONG Y N, TSAO K C, HSIAO M J, et al. SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East[J]. Emerg Microbes Infect, 2020, 9(1):1457-1466. doi: 10.1080/22221751.2020.1782271.
[23]	SU Y C F, ANDERSON D E, YOUNG B E, et al. Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2[J]. mBio, 2020, 11(4):e01610-e01620. doi: 10.1128/mBio.01610-20.
[24]	PEREIRA F. SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring[J]. Biochem Biophys Res Commun, 2021, 550:8-14. doi: 10.1016/j.bbrc.2021.02.080.
[25]	CERAOLO C, GIORGI F M. Genomic variance of the 2019-nCoV coronavirus[J]. J Med Virol, 2020, 92(5):522-528. doi: 10.1002/jmv.25700.
[26]	ALKHANSA A, LAKKIS G, EL ZEIN L. Mutational analysis of SARS-CoV-2 ORF8 during six months of COVID-19 pandemic[J]. Gene Rep, 2021, 23:101024. doi: 10.1016/j.genrep.2021.101024.
[27]	LAHA S, CHAKRABORTY J, DAS S, et al. Characterizations of SARS-CoV-2 mutational profile,spike protein stability and viral transmission[J]. Infect Genet Evol, 2020, 85:104445. doi: 10.1016/j.meegid.2020.104445.
[28]	DE SOUSA E, LIGEIRO D, LERIAS J R, et al. Mortality in COVID-19 disease patients:Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants[J]. Int J Infect Dis, 2020, 98:454-459. doi: 10.1016/j.ijid.2020.07.016.
[29]	WANG R, CHEN J, GAO K, et al. Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants[J]. Commun Biol, 2021, 4(1):228. doi: 10.1038/s42003-021-01754-6.
[30]	HASSAN S S, ALJABALI A A A, PANDA P K, et al. A unique view of SARS-CoV-2 through the lens of ORF8 protein[J]. Comput Biol Med, 2021, 133:104380. doi: 10.1016/j.compbiomed. 2021.104380.
[31]	AMANAT F, STADLBAUER D, STROHMEIER S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans[J]. Nat Med, 2020, 26(7):1033-1036. doi: 10.1038/s41591-020-0913-5.
[32]	GORDON D E, JANG G M, BOUHADDOU M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing[J]. Nature, 2020, 583(7816):459-468. doi: 10.1038/s41586-020-2286-9.
[33]	ERUKAINURE O L, ATOLANI O, MUHAMMAD A, et al. Translational suppression of SARS-COV-2 ORF8 protein mRNA as a Viable therapeutic target against COVID-19: Computational studies on potential roles of isolated compounds from Clerodendrum volubile leaves[J]. Comput Biol Med, 2021, 139:104964. doi: 10.1016/j.compbiomed.2021.104964.

SARS-CoV-2辅助蛋白ORF8的功能及研究进展

The research progress and function of SARS-CoV-2 accessory protein ORF8

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 1

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	祁福敏, 苏睿, 郝剑, 苏丽, 范倩, 李昕, 魏蔚. 显微镜下多血管炎相关间质性肺病合并COVID-19患者疫苗保护作用初探[J]. 天津医药, 2024, 52(7): 683-686.
[2]	吕梦娜, 李建斌, 吴锐. 自身炎症性疾病患者合并COVID-19严重程度的早期预测指标探讨[J]. 天津医药, 2024, 52(5): 528-531.
[3]	谷松涛, 贾玮, 李月川, 张冬睿, 张雅婷, 高淑连, 李娜. COVID-19合并肺血栓栓塞症的临床特点[J]. 天津医药, 2023, 51(8): 873-877.
[4]	钟慕贤, 谢新荣. 糖尿病酮症酸中毒合并新型冠状病毒肺炎的临床特征分析[J]. 天津医药, 2023, 51(12): 1378-1381.
[5]	孙强, 宋维亮. 新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展[J]. 天津医药, 2023, 51(1): 105-108.
[6]	李细媛, 朱智鑫, 赵海龙 . BRAF突变型黑色素瘤的耐药性机制及治疗最新研究进展 #br#[J]. 天津医药, 2022, 50(2): 214-219.
[7]	崔亚琼, 刘薇. 新型冠状病毒感染相关儿童多系统炎症综合征与细胞因子风暴[J]. 天津医药, 2022, 50(12): 1340-1344.
[8]	冯李婷, 王星, 李莉, 吴琦. 天津市输入型新型冠状病毒奥密克戎变异毒株感染者的临床特征分析[J]. 天津医药, 2022, 50(10): 1083-1087.
[9]	王玉亮, 龙艺尹, 陈晓波. SARS-CoV-2变异株的遗传学特征和致病特点[J]. 天津医药, 2022, 50(10): 1103-1109.
[10]	郭晶, 李莉, 吴茜, 李红蔚, 史丽霞, 吴琦. 系统免疫炎症指数对新型冠状病毒肺炎核酸转阴时间的影响[J]. 天津医药, 2021, 49(11): 1188-1192.
[11]	乔志飞, 刘春艳, 李福龙△, 林卫佳, 刘华清, 刘海春, 王磊. 新型冠状病毒肺炎危重型合并肥胖症患者一例[J]. 天津医药, 2020, 48(9): 894-897.
[12]	刘浩, 龙利△, 张继波, 金晟, 余建峰, 覃慧群, 徐敏. 新型冠状病毒肺炎患者血清胱抑素C与炎性因子水平变化及其相关性#br#[J]. 天津医药, 2020, 48(8): 753-756.
[13]	左方田, 李长力, 董照刚, 常新会, 贾明雅, 魏超, 郑喜胜△. 新型冠状病毒肺炎患者的临床特点及与严重程度的相关性分析[J]. 天津医药, 2020, 48(7): 583-587.
[14]	赵磊 , 薛剑 , 王瑜玲△, 戴二黑 , 许尊贵 , 李雅楠 , 敦子倩 , 高会霞 , 戎燕筱 , 陈灿. 石家庄地区新型冠状病毒肺炎患者的临床特征及影像学分析[J]. 天津医药, 2020, 48(7): 588-591.
[15]	袁连方, 柳丽丽, 冯毅. 早期仅症状体征阳性的新型冠状病毒肺炎一例[J]. 天津医药, 2020, 48(7): 603-605.